Recurrent High Risk Myelodysplastic Syndrome Recruiting Phase 2 Trials for Tacrolimus (DB00864)

IndicationStatusPhase
DBCOND0092721 (Recurrent High Risk Myelodysplastic Syndrome)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02861417Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantTreatment